Scailyte Extends Series A to USD 8 Million

Dec 4 2023

We are thrilled to announce the extension of our Series A funding, bringing the total raised amount to USD 8 million.

Accelerating Innovation and Expanding Horizons

These additional resources will play a pivotal role in accelerating Scailyte’s impact in the immuno-oncology landscape, expanding our business partnerships and market footprint. We are committed to solidifying our position as a leading biomarker discovery and translational platform harnessing the power of single-cell omics and proprietary AI algorithms.

Peter Nestorov, CEO & co-founder, shares his excitement, “In the past year, we have gained significant commercial traction, validating the market need for an unbiased and powerful biomarker discovery approach, which delivers reliable and translatable insights from small patient populations. With the newly raised funds, we will expand our presence in the US market, seeking further partnerships with like-minded biotech and pharma companies in the precision oncology space.”

Pascal Koenig, Chair of the Board of Directors, comments,“This additional investment is a testament to the long-term trust and recognition of Scailyte’s potential and tireless efforts. It reaffirms our commitment to advancing the field of precision oncology.”

Thank you for your unwavering support on our journey to transform oncology research. Together, we’re making a difference!

About Scailyte

Scailyte is an ETH Zürich spin-off with a best-in-class artificial intelligence platform for the discovery of complex disease patterns from single-cell data. Our solution provides unprecedented insight into the disease and patients’ biology and enables the discovery of new clinically-relevant biomarker signatures by uncovering human’s hidden “single-cell” secrets.

Scailyte’s proprietary best-in-class data analysis platform ScaiVision™ associates multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc.) with clinical endpoints, such as disease diagnosis, progression, severity, treatment response, and toxicity response to identify ultra-sensitive biomarker signatures and cell functionality states. The performance and clinically-relevant applications of Scailyte’s platform ScaiVision have been demonstrated in well established CAR-T cell therapies and various clinical projects in Oncology and Immunology.

For more information, visit www.scailyte.com and connect on social media @LinkedIn and @Twitter.

ScailyteTM and ScaiVisionTM are registered trademarks proprietary to Scailyte AG.

Recent News

Scailyte and Sanofi Collaboration Solves Critical Manufacturing Challenge for NK Cell Therapy, New Paper Reveals

Scailyte's AI-driven ScaiVision™ platform successfully identified a predictive biomarker for manuf...

Scailyte Awarded CHF 800K Innosuisse Grant to Drive Precision Medicine in Inflammatory Bowel Disease (IBD)

Project AIomics will unite Scailyte's AI discovery platform with the Swiss IBD Cohort and Universit�...

Scailyte and Visterra Partner to Advance Autoimmune Disease Research

Scailyte AG, an AI-driven biomarker discovery company, and Visterra, Inc., a clinical-stage biopharm...

Scailyte Strengthens Its Leadership

Scailyte appoints Tim Foley as Chief Business Officer, Jean-Pierre Rosat as Executive Chair, and Dar...

Scailyte Announces Virginia Savova, PhD as a Strategic and Scientific Advisor

Scailyte Announces Virginia Savova, PhD as a Strategic and Scientific Advisor. Dr. Savova brings str...